Abstract：
Bone metastasis in metastatic breast cancer commonly results in osteolytic lesions due to osteoclast activity, promoting bone destruction and tumor progression. The bioactive fungal isolates, 4-acetyl-antroquinonol B (4-AAQB) and erinacine A, have diverse pharmacological and biological activities. However, their effects on breast cancer bone metastasis treatment remain unclear. Our study aimed to examine the impact of 4-AAQB or erinacine A on breast cancer metastases in bone. The effects of 4-AAQB and erinacine A on breast cancer-induced osteoclastogenesis, breast cancer migration, production of prometastatic cytokine (TGF-β) and marker (MMP-9), as well as potential MAPK signaling transductions were assessed. The results revealed that 4-AAQB and erinacine A effectively suppressed breast cancer-induced osteoclastogenesis and migration, and reduced TGF-β and MMP-9 production via Erk or JNK signaling transductions, specifically in breast cancer cells or in breast cancer cells-induced osteoclasts. Based on these findings, either 4-AAQB or erinacine A showed promise in preventing breast cancer metastases in bone.
摘要：
转移性乳腺癌的骨转移通常由于破骨细胞活性而导致溶骨性病变，促进骨破坏和肿瘤进展。生物活性真菌分离株，4-乙酰基-蒽醌醇B（4-AAQB）和赤霉素A，具有多种药理和生物活性。然而,它们对乳腺癌骨转移治疗的影响尚不清楚.我们的研究旨在研究4-AQB或赤霉素A对乳腺癌骨转移的影响。4-AQB和赤霉素A对乳腺癌诱导的破骨细胞生成的影响,乳腺癌迁移，促转移细胞因子（TGF-β）和标志物（MMP-9）的产生，以及潜在的MAPK信号转导进行了评估。结果表明，4-AAQB和赤霉素A可有效抑制乳腺癌诱导的破骨细胞生成和迁移，并通过Erk或JNK信号转导减少TGF-β和MMP-9的产生，特别是在乳腺癌细胞或乳腺癌细胞诱导的破骨细胞中。基于这些发现,4-AQB或赤霉素A在预防乳腺癌骨转移方面显示出希望。
